Literature DB >> 31764123

Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.

R Andrew Harkins, Sharvil P Patel, Christopher R Flowers.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is clinically heterogeneous. Integration of oral targeted therapies (OTTs) in the management of CLL has fundamentally altered CLL treatment pathways and improved outcomes for patients with CLL.We review the cost-effectiveness of OTTs in the treatment of CLL. We used MeSH (Medical Subject Heading) terms and keywords to search the National Library of Medicine online MEDLINE database (PubMed) for articles related to cost-effectiveness of OTTs in CLL care.Oral targeted therapies add considerable expense to the treatment of CLL for patients and the health care system. Cost-effectiveness analyses of OTTs are not uniform in their conclusions and depend on patient groups selected for analysis. Given the substantial increase in expense associated with integration of OTTs in CLL treatment, cost reduction methods are needed to ensure equitable access to novel therapies for all patients with CLL.

Entities:  

Mesh：

Year:  2019        PMID： 31764123      PMCID： PMC7141587          DOI： 10.1097/PPO.0000000000000411

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  51 in total

1.  NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.

Authors:  Boglarka Mikudina; Melinda Goodall; Amanda I Adler
Journal:  Lancet Oncol       Date:  2017-01-25       Impact factor: 41.316

2.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Authors:  Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

3.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps
Journal:  Blood       Date:  2018-03-14       Impact factor: 22.113

4.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

5.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Authors:  Mohammed Z H Farooqui; Janet Valdez; Sabrina Martyr; Georg Aue; Nakhle Saba; Carsten U Niemann; Sarah E M Herman; Xin Tian; Gerald Marti; Susan Soto; Thomas E Hughes; Jade Jones; Andrew Lipsky; Stefania Pittaluga; Maryalice Stetler-Stevenson; Constance Yuan; Yuh Shan Lee; Lone B Pedersen; Christian H Geisler; Katherine R Calvo; Diane C Arthur; Irina Maric; Richard Childs; Neal S Young; Adrian Wiestner
Journal:  Lancet Oncol       Date:  2014-12-31       Impact factor: 41.316

6.  Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.

Authors:  Richa Sinha; William Ken Redekop
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-12-29

7.  2016 US lymphoid malignancy statistics by World Health Organization subtypes.

Authors:  Lauren R Teras; Carol E DeSantis; James R Cerhan; Lindsay M Morton; Ahmedin Jemal; Christopher R Flowers
Journal:  CA Cancer J Clin       Date:  2016-09-12       Impact factor: 508.702

8.  Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Andrew D Zelenetz; Jacqueline C Barrientos; Jennifer R Brown; Bertrand Coiffier; Julio Delgado; Miklós Egyed; Paolo Ghia; Árpád Illés; Wojciech Jurczak; Paula Marlton; Marco Montillo; Franck Morschhauser; Alexander S Pristupa; Tadeusz Robak; Jeff P Sharman; David Simpson; Lukáš Smolej; Eugen Tausch; Adeboye H Adewoye; Lyndah K Dreiling; Yeonhee Kim; Stephan Stilgenbauer; Peter Hillmen
Journal:  Lancet Oncol       Date:  2017-01-28       Impact factor: 41.316

Review 9.  Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Hema Mistry; Chidozie Nduka; Martin Connock; Jill Colquitt; Theodoros Mantopoulos; Emma Loveman; Renata Walewska; James Mason
Journal:  Pharmacoeconomics       Date:  2018-04       Impact factor: 4.981

Review 10.  Chronic lymphocytic leukemia treatment algorithm 2018.

Authors:  Sameer A Parikh
Journal:  Blood Cancer J       Date:  2018-10-03       Impact factor: 11.037
View more
  1 in total

1.  How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Authors:  R Andrew Harkins; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2020-11-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.